[go: up one dir, main page]

ES2043831T3 - Terapia antiviral para la hepatitis b empleando 2',3'-dideoxinucleosidos. - Google Patents

Terapia antiviral para la hepatitis b empleando 2',3'-dideoxinucleosidos.

Info

Publication number
ES2043831T3
ES2043831T3 ES88307307T ES88307307T ES2043831T3 ES 2043831 T3 ES2043831 T3 ES 2043831T3 ES 88307307 T ES88307307 T ES 88307307T ES 88307307 T ES88307307 T ES 88307307T ES 2043831 T3 ES2043831 T3 ES 2043831T3
Authority
ES
Spain
Prior art keywords
hepadnavirus
virus
dideoxynucleoside
purine
duck hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88307307T
Other languages
English (en)
Inventor
David L J Tyrrell
Morris J Robins
Satoru Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
University of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta filed Critical University of Alberta
Application granted granted Critical
Publication of ES2043831T3 publication Critical patent/ES2043831T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBE UN METODO PARA EL TRATAMIENTO DE INFECCIONES DE HEPADENOVIRUS EN ANIMALES. LOS ANIMALES INFECTADOS POR EL VIRUS DE LA HEPATITIS B HAN DE SER TRATADOS CON LOS 2'',3''DIDEOXINUCLEOXIDOS DE ADENINA, GUANINA, HIPOXANTINA, 2,6 DIAMINOPURINA O VARIOS ANALOGOS DE PURINAS SUSTITUIDAS. VARIOS ANALOGOS 2'',3''- DIDEOXINUCLEOXIDOS DE PURINA INHIBEN AL VIRUS DE LA HEPATITIS B EN CULTIVOS DE HEPATOCITOS > 99% A 1(MU)G/ML. SE DEMUESTRA LA EFICACIA POTENTE EN VIVO DE LA 2,6 - DIAMINO PURINA 2'',3''-DIDEOXINUCLEOXIDO PARA LA ELIMINACION DEL VIRUS DE LA HEPATITIS B DE PATO EN SUERO DE PATOS DE PEKIN.EL EFECTO SELECTIVO SOBRE LA REPLICACION DE HEPADENOVIRUS POR LOS 2'',3''-DEOXINUCLEOXIDOS DE PURINA SE BASA EN EL DESCUBRIMIENTO DE UNA INESPERADA SENSIBILIDAD DE ESTOS A LOS ANALOGOS ANTES MENCIONADOS. ESTOS COMPUESTOS PERMITEN UNA TERAPIA ANTIVIRICA PARA CASOS DE INFECCION AGUDA O PERSISTENTE POR HEPADENOVIRUS.
ES88307307T 1987-08-07 1988-08-08 Terapia antiviral para la hepatitis b empleando 2',3'-dideoxinucleosidos. Expired - Lifetime ES2043831T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17819687A 1987-08-07 1987-08-07

Publications (1)

Publication Number Publication Date
ES2043831T3 true ES2043831T3 (es) 1994-01-01

Family

ID=22651606

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88307307T Expired - Lifetime ES2043831T3 (es) 1987-08-07 1988-08-08 Terapia antiviral para la hepatitis b empleando 2',3'-dideoxinucleosidos.

Country Status (9)

Country Link
EP (1) EP0302760B1 (es)
JP (1) JP2899292B2 (es)
KR (1) KR940010441B1 (es)
AT (1) ATE78692T1 (es)
AU (1) AU623341B2 (es)
CA (1) CA1327000C (es)
DE (1) DE3873207T2 (es)
ES (1) ES2043831T3 (es)
HK (1) HK1000112A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252060B1 (en) 1988-07-07 2001-06-26 Nexstar Pharmaceuticals, Inc. Antiviral liponucleosides: treatment of hepatitis B
US6599887B2 (en) 1988-07-07 2003-07-29 Chimerix, Inc. Methods of treating viral infections using antiviral liponucleotides
US5013829A (en) * 1989-04-26 1991-05-07 University Of Iowa Research Foundation Stable congener of 2',3'-dideoxyadenosine
JPH04501857A (ja) * 1989-05-15 1992-04-02 アメリカ合衆国 肝炎の治療方法
EP0472595A4 (en) * 1989-05-15 1992-07-08 Us Commerce Method of treatment of hepatitis
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
DE4110977A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Substituierte 2',3'-didesoxy-5-trifluormethyluridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
DE4207363A1 (de) * 1992-03-04 1993-09-09 Max Delbrueck Centrum Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
GB9226927D0 (en) * 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
EP0717628A4 (en) * 1993-09-10 1999-05-26 Univ Emory NUCLEOSIDES WITH ACTIVITY AGAINST THE HEPATITIS B VIRUS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions

Also Published As

Publication number Publication date
EP0302760A3 (en) 1989-08-09
EP0302760B1 (en) 1992-07-29
AU623341B2 (en) 1992-05-14
AU2050288A (en) 1989-02-09
ATE78692T1 (de) 1992-08-15
EP0302760A2 (en) 1989-02-08
DE3873207T2 (de) 1993-01-07
JPH0285215A (ja) 1990-03-26
KR940010441B1 (ko) 1994-10-22
KR890003384A (ko) 1989-04-14
HK1000112A1 (en) 1997-12-05
DE3873207D1 (en) 1992-09-03
JP2899292B2 (ja) 1999-06-02
CA1327000C (en) 1994-02-15

Similar Documents

Publication Publication Date Title
ES2043831T3 (es) Terapia antiviral para la hepatitis b empleando 2',3'-dideoxinucleosidos.
KR900701817A (ko) 뉴클레오사이드 유도체와 그의 제조방법
DE122007000062I1 (de) Beta-L-2'-deoxynukleoside für die Behandlung von Hepatitis-B-Virus
ES8802616A1 (es) Un procedimiento para preparar una formulacion farmaceutica que contiene 3'-azido-3'-desoxitimidina o uno de sus derivados farmaceuticamente aceptables.
DE69025834D1 (de) Antivirale Verbindungen
PA8483101A1 (es) Compuestos quimicos
FI20080432A (fi) L-nukleosidejä hepatiitti-B-viruksen ja Epstein-Barr-viruksen hoitamiseksi
KR930006036A (ko) 퓨린 및 피리미딘의 불포화 비환식 포스포네이트 유도체
RO85288A (ro) Procedeu de preparare a unor derivati ai guaninei
SE8602981D0 (sv) Novel medicinal use
KR920002623A (ko) 특정 뉴클레오사이드의 카보사이클릭 동족체
KR910000734A (ko) 네플라노신 유도체
KR940005656A (ko) 항 바이러스 및 항암 활성을 갖는 2'-데옥시-2', 2'-디플루오로(2,6,8-치환된) 퓨린 뉴클레오시드 및 중간체
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
AU1083488A (en) Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus
KR900018095A (ko) 신규 화합물들
SE8803309D0 (sv) Antiviral agents
SE7702231L (sv) Sett att framstella en substituerad purin
DE69019404D1 (de) Derivate von Penciclovir zur Behandlung von Hepatitis-B-Infektionen.
EP0286825A3 (en) Use of 3'-fluro-3' deoxythymidine for the manufacture of a medicament for the treatment of virus infections
KR960704464A (ko) 포유동물 세포에서의 뉴클레오사이드와 뉴클레오베이스 수송억제 방법 및 바이러스 복제억제 방법(method for inhibiting nucleoside and nucleoside transport and virus replication in mammalian cells)
Thompson et al. Effect of Ethionine and Other Materials on Semliki Forest Virus Infection in the Mouse.
KR900016235A (ko) 옥세타노신의 인산에스테르 유도체와 그 제조방법 및 용도
Dianzani et al. Antiviral Drugs
KR950703976A (ko) 아시클로비르 유사 화합물과 2′-비닐 치환 뉴클레오시드 유사체를 함유하는 바이러스 감염 치료용 조성물(Compositions Containing Acyclovir-Like Compounds and 2′-Vinyl substituted Nucleoside Analogs for the Treatment of Viral Infections)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 302760

Country of ref document: ES